Stephens Investment Management Group LLC Buys 43,680 Shares of Medpace Holdings, Inc. $MEDP

Stephens Investment Management Group LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 36.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 162,797 shares of the company’s stock after acquiring an additional 43,680 shares during the period. Medpace accounts for about 1.1% of Stephens Investment Management Group LLC’s portfolio, making the stock its 25th biggest position. Stephens Investment Management Group LLC’s holdings in Medpace were worth $78,173,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace in the fourth quarter worth $30,000. Elyxium Wealth LLC acquired a new position in Medpace in the fourth quarter valued at about $30,000. Quarry LP acquired a new position in Medpace in the third quarter valued at about $35,000. Finally, Bayban bought a new stake in Medpace during the fourth quarter worth about $44,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on MEDP. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BMO Capital Markets reduced their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Robert W. Baird decreased their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Royal Bank Of Canada lowered their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $467.08.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is currently owned by corporate insiders.

Medpace Price Performance

Medpace stock opened at $557.60 on Friday. The stock has a market cap of $15.93 billion, a PE ratio of 35.05, a P/E/G ratio of 2.83 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $306.70 and a 12-month high of $628.92. The business’s 50-day moving average price is $453.88 and its two-hundred day moving average price is $496.63.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the prior year, the business earned $3.67 earnings per share. The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.